Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Open-label, Post-approval Observational Study of Elpida® Used in the First Line Therapy for HIV-1 Infected Patients With the Background of Standard Baseline ART (NNRTI + 2 NRTIs)

NCT03706950 is registered in ClinicalTrials.gov with Viriom as lead sponsor.

NCT NCT03706950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03706950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Open-label, Post-approval Observational Study of Elpida® Used in the First Line Therapy for HIV-1 Infected Patients With the Background of Standard Baseline ART (NNRTI + 2 NRTIs)
Lead sponsor
Viriom
Phase
Observational
Overall status
Unknown status
Start date
March 15, 2018
Completion date
December 31, 2022
Enrollment
2,000 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection